TaiGen Biopharmaceuticals Holdings Ltd (太景醫藥研發控股) on Wednesday said that it is venturing into the North American market through its partnership with Luminarie Canada Inc, which would develop and commercialize its antibiotic Taigexyn in Canada.
Luminarie would also help develop the drug in Australia and New Zealand, TaiGen said, after the two companies signed an exclusive licensing agreement, with Luminarie to assume all associated costs for the antibiotic’s development.
In exchange for the exclusive rights, Luminarie is to pay TaiGen milestone payments upon the achievement of the following: Luminarie’s application for marketing approval, application for a manufacturing drug license, obtaining marketing approval, obtaining a license and setting the drug price under the healthcare insurance system, TaiGen said.
Photo: Chen Yung-chi, Taipei Times
Luminarie would purchase Taigexyn at a pre-negotiated price from TaiGen for its commercialization, it said.
TaiGen did not reveal how much the milestone payments would be, or when its Canadian partner plans to apply for regulatory approvals in the three markets.
TaiGen also licensed Luminarie to seek another company that would commercialize Taigexyn in the US, to leverage the Canadian pharmaceutical company’s network in North America, it said.
“We are interested in Luminarie because we share the same innovative vision for Taigexyn,” TaiGen chairman Philip Huang (黃國龍) said in a statement. “By partnering with Luminarie, TaiGen would be able to tap into these developed markets where the need for such a novel antibiotic to treat drug-resistant infection is very high.”
The company’s business strategy is to work with foreign partners to expand into overseas markets, as they have stronger connections in the pharmaceutical environment abroad and better familiarity with regulations, a TaiGen official told the Taipei Times by telephone yesterday.
Through the partnership with Luminarie, TaiGen has expanded the drug into 35 markets, including Taiwan and China, said the official, who declined to be named.
Taigexyn is a safe and effective antibiotic for the treatment of bacterial infections, including those caused by drug-resistant bacteria, the company said.
TaiGen reported a cumulative revenue of NT$13.96 million (US$479,297) in the first eight months of the year, up 17.4 percent from a year earlier, as some doctors used Taigexyn to treat COVID-19 patients who also had bacterial infections, it said.
RESTRUCTURING: Taichung and Taoyuan profited most from local firms moving back high-end manufacturing amid the US-China decoupling of trade ties, the ministry said The government’s “Invest in Taiwan” initiative might this year see NT$627.1 billion (US$21.7 billion) of investment pledges realized, with several firms raising stakes and two dropouts due to customer losses, Minister of Economic Affairs (MOEA) Wang Mei-hua (王美花) said yesterday. Wang made the statement at the monthly meeting of the Third Wednesday Club, a local trade group featuring the top 100 firms of each business sector. Since early last year, the government has launched three programs intended to help local companies grapple with US-China trade rows and the COVID-19 pandemic, mainly through moving production lines back to Taiwan. Thus far, the ministry
JOBS AT RISK? Most Cathay Dragon routes are to be operated by Cathay Pacific or a subsidiary, but it was unclear how Taiwanese workers would be affected Cathay Pacific Airways Ltd (國泰航空) yesterday said it is planning new flight services for Taiwan as it announced a corporate restructuring that included the shutdown of its regional subsidiary, Cathay Dragon (國泰港龍), and could lead to job cuts in Taiwan. Cathay Pacific said the shutdown means that the one round-trip service between Taichung and Hong Kong per day and seven round-trip services between Kaohsiung and Hong Kong operated by Cathay Dragon prior to the COVID-19 pandemic would be terminated. “The parent company is planning a new schedule between Taiwan and Hong Kong,” Cathay Pacific assistant manager for corporate communications Moses Hou (侯恩錫)
OVERHEATED MARKET?: The gauge would be designed to provide more reliable information than private-sector data, and help improve policymaking, the council said The National Development Council (NDC) is considering creating a business climate index on Taiwan’s property market, allowing policymakers to better monitor market movements and intervene if necessary, NDC Minister Kung Ming-hsin (龔明鑫) said yesterday. Kung made the remarks at a meeting of the legislature’s Economic Committee where lawmakers from across party lines voiced concerns about housing price hikes driven by capital repatriation. Kung said that the council is assessing the possibility of creating an index designed to provide more accountable and transparent information than data provided by private-sector market analysts, and could help improve policymaking. The council would compile a report on
STOCK MARKETS TAIEX closes slightly higher The TAIEX closed slightly higher yesterday as market sentiment remained cautious over the Nov. 3 US presidential election. Contract chipmaker Taiwan Semiconductor Manufacturing Co (TSMC, 台積電) was again the anchor stabilizing the broader market, preventing the main board from falling into negative territory at the end of the session, dealers said. The TAIEX closed up 14.88 points, or 0.12 percent, at 12,877.25, on turnover of NT$167.982 billion (US$5.81 billion). TSMC, the most heavily weighted stock on the local market, rose 0.44 percent after fluctuating between NT$451 and NT$456. The semiconductor subindex and the bellwether electronics sector